Drugs / COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin
COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin
targets COL7A1 via restoration
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04186650 | Jan 2020 → Jun 2027 expected | recessive dystrophic epidermolysis bullosa | French National Institute of Health and Medical Research | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04186650 ↗ |
| Action | Restore | “genetically corrected ex vivo with a secure Self INactivating (SIN) retroviral vector expressing the COL7A1 cDNA” NCT04186650 ↗ |
| Route | Other | “Each patient will be grafted sequentially at Necker Hospital in Paris using autologous genetically corrected skin equivalents” NCT04186650 ↗ |
| Target | COL7A1 | “vector expressing the COL7A1 cDNA” NCT04186650 ↗ |